

CASE REPORT

Breast

Artifacts on Magnetic Resonance Imaging from Electronic Identification Enablement in Silicone Gel Implants Are Not Negligible

Kathinka D. Kurz, MD, PhD*†
Øystein Kallevåg, MSc*
Kenneth Austrått, MSc‡
Bodil Styr, MD*
Jon Bjarne Leiknes, MD*§
Pål Krøger, MD¶

Summary: Breast implants filled with silicone gel are used worldwide for cosmetic reasons, or breast reconstruction following risk-reducing or therapeutic mastectomy. The importance of identifiable implants is undeniable. A recent development has been the labeling of the implants with a radio-frequency device micro responder chip (RFID). We examined a patient with silicone implants containing RFID chips with magnetic resonance imaging and were surprised by the artifacts caused by the RFID chip. We raise the question if the benefits of RFID-labeled silicone implants outweigh the drawbacks of magnetic resonance artifacts caused by the RFID chip itself. (*Plast Reconstr Surg Glob Open 2021;9:e3941; doi: 10.1097/GOX.000000000000003941; Published online 22 November 2021.)*

atients with silicone filled breast implants will likely need radiological breast imaging several times during their lifespan. The lifetime risk of developing breast cancer in the western world is 12%. The risk might be significantly higher for women with a positive family or personal history of breast cancer or genetic predisposition for breast cancer. Magnetic resonance imaging (MRI) is the gold-standard diagnostic tool for detecting and assessing breast lesions in women with breast implants, and as such, image quality is of utmost importance.

CASE REPORT

A 40-year-old female patient detected a palpable lump in the upper outer quadrant of her left breast in July 2020. Before this, she was healthy. The patient underwent bilateral breast augmentation with silicone implants placed in the submuscular plane for cosmetic reasons 18

From the *Stavanger Medical Imaging Laboratory, Department of Radiology, Stavanger University Hospital, Stavanger, Norway; †Department of Electrical Engineering and Computer Science, BMDLab, University of Stavanger, Stavanger, Norway; ‡Department of Innovation, Stavanger University Hospital, Stavanger, Norway; \$Department of Clinical Science, University of Bergen, Bergen, Norway; and ¶Department of Plastic, Reconstructive and Hand Surgery, Stavanger University Hospital, Stavanger, Norway.

Received for publication June 30, 2021; accepted September 28, 2021.

Copyright © 2021 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of The American Society of Plastic Surgeons. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. DOI: 10.1097/GOX.00000000000003941

years ago. Mammography and ultrasound of both breasts were performed at a private institute. Corresponding to the palpable mass, a lobulated, circumscribed hypoeccogenic mass was found on ultrasound. The lesion was not BI-RADS classified. Cytology from ultrasound-guided fine needle aspiration revealed no typical malignant breast epithelium cells. Due to the age of the silicone implants, a replacement of the old implants was planned simultaneously with removal of the palpable mass. The new implants were placed in the same submuscular envelope and were of Motiva SmoothSilk/SilkSurface (MSS) implant type (Establishment Labs Holdings, Alajuela, Costa Rica) (Fig. 1). However, histology revealed a 16mm infiltrative carcinoma of no special type pT1cN2a (4/9) M0 grade 3, surrounded by ductal carcinoma in situ grade 3, estrogen and progesterone receptor negative, ERBB2 (formerly HER2) positive, and the patient was referred to our hospital. During staging of the patient, an MRI of the liver was planned on a 3T Philips Ingenia MRI system (Philips, Best, the Netherlands). Surprisingly, there were large artifacts arising from the posterior surface of the silicone implants, which compromised the image quality of the scout images of the liver (Figs. 2, 3). An examination of the liver was then performed on a 1.5 T MRI machine where the artifacts were minimized, after slight sequence customization.

DISCUSSION

The MSS implants contain a radio-frequency device micro responder (RFID-M) (JAMM Technologies, Minneapolis Minn.) integrated within the posterior inner surface of the implant. 1,2 The RFID-M measures 2.1×9 mm (Fig. 2). With the RFID-M, it is possible to provide information about the implants through a 15-digit electronic serial

Disclosure: The authors have no financial interest to declare in relation to the content of this article.



Fig. 1. Motiva SmoothSilk/SilkSurface implant type (Establishment Labs Holdings, Alajuela, Costa Rica). The radio-frequency device micro responder (RFID-M) (JAMM Technologies, Minneapolis Minn.) is integrated in the posterior inner surface of the implant.




Fig. 2. Survey from Philips Ingenia 3.0T scanned with dStream anterior coil and posterior coil. bFFE-sequence in the coronal plane (FOV 450 mm, TR: 3.02 ms, TE: 1.51 ms, slice thickness 10 mm, 20 slices, matrix: 256×224 , BW 1924 Hz, flip angle 60 degree, acquisition time 15 s. The survey shows major artifacts over the silicone implants (arrows). bFFE, balanced Fast Field Echo; BW, bandwidth; FOV, field of view; TR, repetition time; TE, echo time. The two upper arrows point at the artifacts from the RFID-Ms in the silicone prosthesis. The two arrows below show more distant artifacts caused by the RFID-Ms, leading to image quality impairment of the liver parenchyma.




Fig. 3. Survey in the coronal plane from the liver. Equipment and acquisition parameters are the same as in Figure 2. Artifacts from the RFID-M are also visible over the liver parenchyma (arrows).

number, when scanned by a hand-held reader. 1,2 Traceability of breast implants by using a unique device identification is mandatory in both Europe and in the United States.^{3,4} Unique device identification is commonly a serial number, that links the specific implant to production date, expiration date, serial number, and batch number. According to legislation, the implants must be marked by a unique device identification, with at least a physical implant card and registered in the electronic patient record.^{3,4} RFIDbased tracking of the medical implant therefore represents a higher level of tracing than legally obligated. RFID is not a new technique, and has been used widely (ie, in veterinary medicine) for decades.⁵ The RFID-M inherently contains magnetic metal, and due to the strong magnetic field in the MRI scanner, the metal unfortunately causes artifacts on the MRIs. One prior study on MRI artifacts caused by the RFID-M in the MSS implants asserts that the possible harm of artifacts is magnitudes smaller than the benefits of traceable implants.⁶ A study assessing safety and image quality of MRI with RFID-tags showed image distortion up to 8 cm from the RFID on a 1.5 T scanner. Further, the study suggests not to use gradient echo sequences with a present RFID-tag.3 Another study measured artifacts in 42.9 cm3 on T1-weighted MRIs and 60.5 cm³ on T2-weighted images, which are substantial volumes of tissue.7

Traceability of implants is important, however, in our patient, the artifacts were not negligible and caused problematic artifacts in the liver, which is not located adjacent to the chip. ^{8,9} We are aware of the possibility to use a weaker field strength, which we performed on this patient, and adjust the MRI sequences to be more robust against metal artifacts. Nonetheless, this requires knowledge and the availability of MRI machines that vary in magnetic

field strength, and we are concerned about the detection and characterization of pathology in the breast near the RFID-M where the artifacts are expected to be even larger compared with the artifacts in the liver in our patient. Nelson and coauthors state that the cancer detection rate improves in the area of artifacts if additional diagnostic modalities like ultrasound are used, but the tissue located dorsal to the implants is often suboptimally accessible with ultrasound and MRI is the imaging method of choice.^{6,8-11} Implants may also rotate, and the artifacts will subsequently cover more breast tissue compared with the dorsal position of the RFID-M.² We must not forget that breast implants have become common in many parts of the world, and a substantial number of the patients with an increased risk of developing breast cancer choose to receive silicone implants. It is, in our opinion, of uttermost importance that the implants do not complicate early detection of cancer unnecessarily.¹² Artifacts from the RFID-M in the sequences necessary for cancer detection have only been studied in one single-institution study on one MRI scanner with a 1.5 T field strength. Even on a 1.5 T scanner, the artifact volumes were substantial, and several different sequences are interesting to assess for a more complete picture of the impact of the artifacts caused by RFID-M.

We find it worthwhile to discuss the potential draw-backs of compromised MRI quality caused by RFID-M. Even if minimizing the artifacts and their effects is possible, MRI is such an important diagnostic tool that it should be imperative to find solutions for tracing implants that do not interfere with magnetism or with other imaging modalities used in breast and cancer diagnostics. ^{11,12} If the use of RFID-M is desired, systematic studies that evaluate the artifacts from the RFID regarding size, different

commonly used sequences, different MRI scanners, and field strengths should be conducted to have a better understanding of potential risks regarding cancer diagnostics caused by MRI artifacts in comparison with the benefits provided by RFID-M tagged implants.

CONCLUSIONS

In our opinion, RFID-M used in some breast implants is not sufficiently evaluated regarding artifacts on MRI. There is a need for studies evaluating the impact of the chips on the MRI quality in women who already have implants with RFID-M.

Kathinka D. Kurz, MD, PhD

Department of Radiology, Stavanger University Hospital Postboks 8100 4068 Stavanger Norway

E-mail: kathinka.dehli.kurz@sus.no

ACKNOWLEDGMENT

The authors have obtained written consent from the patient for publishing the case report.

REFERENCES

- Motiva implants. Innovation for Enhanced Safety. Available at https://motivaimplants.com/why-motiva/innovationfor-enhanced-safety/#q-inside-safety-technology. Accessed February 2020.
- Munhoz AM, Chala L, Guedes de Melo G, et al. Usefulness of radio frequency identification device in diagnosing rotation of motiva smoothsilk implants after augmentation mammoplasty. Plast Reconstr Surg Glob Open 2019;7:e2597.

- Directive 2017/745/EU. Regulation on medical devices European Parliament, Council of the European Union. Available at http://data.europa.eu/eli/reg/2017/745/oj. Accessed April 2017.
- FDA. FDA. (2020,0630). Compliance Dates for UDI Requirements. Available at https://www.fda.gov/medical-devices/unique-device-identification-system-udi-system/compliance-dates-udi-requirements. Accessed September 2020.
- Gabel AA, Knowles RC, Weisbrode SE. Horse identification: a field trial using an electronic identification system. J Equine Vet Sci 1988;8:172–175.
- Nelson MT, Brattain KA, Williams JM. Does electronic identification enablement for silicone gel implants impact patient safety? J Surg Open Access 2018;4;1,1–7. 2
- Munhoz AM, Chala L, de Melo G, et al. Clinical and MRI evaluation of silicone gel implants with RFIDM traceability system: a prospective controlled cohort study related to safety and image quality in MRI follow-up. *Aesthetic Plast Surg.* 2021. [E-pub ahead of print.]
- 8. Powell LE, Andersen ES, Nigro LC, et al. Breast implants: a historical review with implications for diagnosis and modern surgical planning. *Ann Plast Surg.* 2021;87:211–221.
- Rivera JC. A historical view of breast implants: Controversy on silicones and breast implant associated -anaplastic large cell lymphoma. Ann Chir Plast Esthet. 2020;65:1–6.
- Green LA, Karow JA, Toman JE, et al. Review of breast augmentation and reconstruction for the radiologist with emphasis on MRI. Clin Imaging. 2018;47:101–117.
- Azzi AJ, Gornitsky J, Viezel-Mathieu A, et al. The impact of implant location on breast cancer characteristics in previously augmented patients: a systematic literature analysis. J Cancer Prev. 2018;23:93–98.
- 12. Fei X, Li S, Gao S, et al. Application safety evaluation of the radio frequency identification tag under magnetic resonance imaging. *Biomed Eng Online*. 2014;13:129.